Current Smoking, Not a History of Smoking is a Risk factor for Metastatic Presentation in Surgical Colon Cancer Patients

574 Background: Bevacizumab has been approved by the FDA for first-line treatment in combination with chemotherapy for metastatic colon cancer. Although bevacizumab extends progression free survival and overall survival for many metastatic colon cancer patients, primary cancer site has not been examined as a predictor of its effectiveness. Methods: Data regarding bevacizumab treatment for colorectal cancer were abstracted from the medical record of 175 patients treated at a large multi-specialty clinic. Data were collected regarding demographics, body mass index, weight loss, lifestyle variables (smoking status, drinking habit), history of colon polyps, family history of cancer, primary site of tumor in the colon, tumor stage, lymph node involvement, metastasis, tumor grade of metastasis, cancer cell type, symptoms related to the cancer, and other comorbidities (cardiovascular disease, diabetes mellitus, Crohn's disease, diverticulitis, and irritable bowel syndrome).Tumor response was measured by radiologic and biochemical markers. Univariate and multivariate analyses were performed using Fisher's exact test, Wilconox rank sum test, and unconditional logistic regression modeling. Results: Univariate analysis demonstrated that positive tumor response was positively correlated with blood in stool (p=0.0301), advanced lymph node stage (p=0.048), and adenocarcinoma cancer cell type (p=0.0387), but negatively correlated with chemotherapy treatment of the primary tumor (p=0.0387) and primary site of the colon cancer (p=0.0328). Multivariate stepwise logistic regression analysis demonstrated that patients with primary tumor located in the transverse or descending/sigmoid colon were more likely (odds ratio=5.88, 95% confidence interval: 1.72–20.00; p=0.0046) to have a positive tumor response than patients whose primary tumor site was cecal/ascending colon. Conclusions: Primary site of metastatic colon cancer may influence the effectiveness of bevacizumab therapy. Future randomized, controlled trials are needed to examine the primary site as a predictor of tumor response in metastatic colon cancer patients using bevacizumab therapy. No significant financial relationships to disclose.

Download Full-text

Tumor ploidy as a risk factor for disease recurrence and short survival in surgically-treated dukes' B2 colon cancer patients

Journal of Surgical Oncology ◽

10.1002/jso.2930590408 ◽

1995 ◽

Vol 59 (4) ◽

pp. 239-242 ◽

Cited By ~ 12

Author(s):

Dattatreyudu Nori ◽

Ofer Merimsky ◽

Engracio Samala ◽

Daisy Saw ◽

Engracio Cortes ◽

...

Keyword(s):

Colon Cancer ◽

Risk Factor ◽

Cancer Patients ◽

Disease Recurrence ◽

Short Survival ◽

Tumor Ploidy

Download Full-text

P1571Atrial fibrillation is an independent predictor of mortality in hospitalized cancer patients

European Heart Journal ◽

10.1093/eurheartj/ehz748.0331 ◽

2019 ◽

Vol 40 (Supplement_1) ◽

Author(s):

A H Malik ◽

S Shetty ◽

S Malik

Keyword(s):

Atrial Fibrillation ◽

Colon Cancer ◽

Risk Factor ◽

Hospital Mortality ◽

Cancer Patients ◽

Cancer Diagnosis ◽

Independent Risk Factor ◽

Attributable Mortality ◽

Patients With Cancer ◽

Hospitalised Patients

Abstract Background Atrial fibrillation (AF) is prevalent in patients with cancer. We performed a study to evaluate the outcomes associated with hospitalised cancer patients with AF. Methods The Nationwide Inpatient Sample was used to identify patients with a cancer diagnosis, who were found to have atrial fibrillation from the years 2002–2014. Descriptive statistics for mortality were calculated using univariate and multivariate model for each cancer, and we identified the type of cancer associated with the highest inpatient mortality. We also calculated the percentage of hospital mortality attributable to AF. Results 12,410,290 (nationwide estimate) patients with a cancer diagnosis were identified, and 8.2% of them had AF. In a multivariate adjusted model for various relevant comorbidities, age, gender and race, AF was also found to be an independent risk factor for higher in-hospital mortality in cancer patients, odds ratio (OR) 1.25 (95% CI 1.23, 1.28, p<0.0001). Colon cancer was found to be associated with the worst outcomes and the highest mortality. In cancer patients, the incident percentage of hospital mortality attributed to AF was 46.7%, population attributable mortality risk of was 7.17%, and number needed to harm was 21 (p<0.0001). Conclusion AF conferred significant morbidity and was found to be an independent risk factor for increased mortality in hospitalised patients with cancer. Colon cancer was found to have the strongest association of worst outcomes in hospitalized patients with AF. Acknowledgement/Funding None

Download Full-text

Tumor Ploidy as a Risk Factor for Disease Recurrence and Short Survival in Surgically Treated Dukes’ B2 Colon Cancer Patients

Tumor Biology ◽

10.1159/000217969 ◽

1996 ◽

Vol 17 (2) ◽

pp. 75-80 ◽

Cited By ~ 6

Author(s):

Dattatreyudu Nori ◽

Ofer Merimsky ◽

Daisy Saw ◽

Engracio Cortes ◽

Ellen Chen ◽

...

Keyword(s):

Colon Cancer ◽

Risk Factor ◽

Cancer Patients ◽

Disease Recurrence ◽

Short Survival ◽

Tumor Ploidy

Download Full-text

Patient Awareness of Head and Neck Cancer Risk Factors: Assessment of the General Otolaryngology Population

Journal of Clinical Otorhinolaryngology ◽

10.31579/2692-9562/021 ◽

2021 ◽

Vol 3 (3) ◽

pp. 01-05

Author(s):

Garrett Ni ◽

Carolyn DeBiase ◽

Neil Gildener-Leapman ◽

Lisa Galati

Keyword(s):

Risk Factors ◽

Risk Factor ◽

Head And Neck Cancer ◽

Cancer Risk ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Chewing Tobacco ◽

Cancer Risk Factors ◽

History Of

Objective: The general public’s knowledge of the risk factors for head and neck cancer is insufficient. The level of awareness of such risk factors amongst the otolaryngology clinic patient population has not yet been elucidated in the literature. Method: This individual cohort study took place at a tertiary academic center. A survey was designed and administered to all patients who presented to otolaryngology clinic from 2017 to 2018 to assess knowledge of head and neck cancer risk factors. The main outcome measures were percentage of correct responses for each cancer risk factor and comparison of percent correct between cancer and non-cancer patients. Results: A total of 510 patients were enrolled in the study including 69 patients (13.5%) with a history of head and neck cancer. The most well recognized risk factors by all patients were cigarettes (83.7%) and chewing tobacco (77.5%). Twenty-nine percent of patients correctly identified alcohol as a risk factor. Additional risk factors were poorly recognized. Cancer patients had a similar or better correct response rate than non-cancer patients except for chewing tobacco (68.1% vs 78.9% respectively). Conclusion: The general otolaryngology clinic population, especially patients with a history of head and neck cancer, demonstrated improved knowledge of some risk factors for head and neck cancer, but insufficient awareness of alcohol and HPV transmissible behaviors.

Download Full-text

The activity of serum beta-galactosidase in colon cancer patients with a history of alcohol and nicotine dependence: preliminary data

Postępy Higieny i Medycyny Doświadczalnej ◽

10.5604/17322693.1064081 ◽

2013 ◽

Vol 67 ◽

pp. 896-900 ◽

Cited By ~ 4

Author(s):

Napoleon Waszkiewicz ◽

Sławomir Dariusz Szajda ◽

Magdalena Waszkiewicz ◽

Aleksandra Wojtulewska-Supron ◽

Agata Szulc ◽

...

Keyword(s):

Colon Cancer ◽

Cancer Patients ◽

Nicotine Dependence ◽

Preliminary Data ◽

History Of ◽

Beta Galactosidase

Download Full-text

Mortality risk factors and survival of colon cancer patient.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e14653 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e14653-e14653

Author(s):

Runhua Shi ◽

Manga Devi Kodali ◽

Stephani Chang Wang ◽

Kalyana C Lavu ◽

Lihong Liu ◽

...

Keyword(s):

Risk Factors ◽

Colon Cancer ◽

Cancer Patients ◽

Household Income ◽

Cancer Survival ◽

Rank Test ◽

Annual Household Income ◽

Life Styles ◽

Increased Risk ◽

History Of

e14653 Background: It is estimated that 142,820 people will be diagnosed and 50,830 will die from colon cancer in U.S. in 2013. The known risk factors include age (>50 years old), personal history of colon polyp(s) and Inflammatory bowel disease, family history of colon cancer, hereditary syndromes, Black race, type II Diabetes Mellitus, obesity, physical inactivity, smoking and alcohol use. In order to improve colon cancer survivorship, current study explores factors that affect it. Methods: Data of 524,613 colon cancer patients between 1973 and 2009 was obtained from the Surveillance Epidemiology and End Results (SEER) program. Factors evaluated in this study were age at diagnosis, gender, race, annual household income, education, unemployment, and smoking. Clinical factors evaluated include SEER historic stage and treatments received. The definition of these factors was based on the SEER data dictionary. Kaplan-Meier method and log rank test was used to estimate and compare survivals. Cox regressions were used to identify risk factors that affect survival. Results: Characteristics of this half millions colon cancer patients were 51.3% of males, 84.4% of whites, and 70% of adjusted household income <$50,000. Primary site: Sigmoid Colon (30.84%), Cecum (22.7%), Ascending Colon (9.42%), and others (9.42%). Stage: Localized (37%), Regional (36.26%), Distant (20.01%), and Unstaged (6.63%). In multivariate analysis, adjusting for other factors, age (≤49 vs. 60-69, HR=0.57), female gender (HR=0.87), stage (localized vs. distant stage, HR= 0.15) and race (Black HR=1.38, vs. Asian) are significant factors in colon cancer survival. People living in areas with a high percentage of smokers have increased risk by 8%. People living in areas of higher unemployment have 6% increased risk. Household income and education level have relatively less effect on colon cancer survival (40-55k vs. 0-40k, HR=1.02). Conclusions: We conclude that in a large database, age, race, stage, smoking, and unemployment have significant impact on colon cancer survival. Other factors such as insurance status, detailed treatments, screening effect, individual life styles and etc. need further investigation.

Download Full-text

Recurrence risk factors and outcome stratification in stage II colon cancer patients: A subanalysis of the SACURA trial.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.3611 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. 3611-3611

Author(s):

Megumi Ishiguro ◽

Eiji Nakatani ◽

Hideki Ueno ◽

Toshiaki Ishikawa ◽

Hiroyuki Uetake ◽

...

Keyword(s):

Risk Factors ◽

Colon Cancer ◽

Risk Factor ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Recurrence Rate ◽

Clinicopathological Characteristics ◽

Stage Ii ◽

Risk Factors For Recurrence ◽

Stage Ii Colon Cancer

3611 Background: Efficacy of adjuvant chemotherapy for stage II colon cancer is still controversial. We conducted the SACURA trial, a phase III study which evaluated the superiority of 1-year adjuvant treatment with oral tegafur-uracil (UFT) to surgery alone in stage II colon cancer. However, survival benefit of 1-year UFT to surgery alone was not demonstrated (ASCO2016 abst#3617). We herein aimed to identify risk factors for recurrence in the stage II patients “without adjuvant chemotherapy”, and to stratify the prognosis by using these factors. Methods: Among a total of 982 patients without adjuvant chemotherapy enrolled to the SACURA trial, we extracted the factors correlated to recurrence using a univariate and multivariate Cox proportional hazard model. 943 and 935 patients in the surgery alone group and UFT group were divided to subgroups according to the number of risk factors, and the recurrence rate in each subgroup was evaluated. Results: Among the conventional clinicopathological characteristics, the multivariate analysis identified pT4, elevated CEA, and examined lymph nodes less than 12 as significant risk factors for recurrence. The rate of patients with 0, 1, 2, and 3 risk factors were 45.0%, 42.4%, 11.5%, and 1.1%, respectively. The recurrence rate for each subgroup was shown in the table: the recurrence rate increased with number of risk factors, while 10.2% of patients without any risk factors developed recurrence. Difference in the recurrence rate between the treatment groups was significant in patients without risk factor, marginal in patients with 1 risk factor, and none in patients with >1 factors. Conclusions: pT4, elevated CEA, and examined lymph nodes less than 12 were identified as risk factors for recurrence in stage II colon cancer patients. The recurrence rate was divided by the number of these risk factors, but we could not extract the very-low risk group in whom adjuvant therapy is unnecessary. Induction of novel risk factors other than conventional clinicopathological characteristics is recommended. Clinical trial information: NCT00392899. [Table: see text]

Download Full-text

Smoking Cessation after Bladder Cancer Diagnosis

Acta Médica Portuguesa ◽

10.20344/amp.9106 ◽

2018 ◽

Vol 31 (2) ◽

pp. 101 ◽

Cited By ~ 1

Author(s):

Paulo Mota ◽

Pedro Miguel Sousa ◽

Francisco Botelho ◽

Emanuel Carvalho-Dias ◽

Agostinho Cordeiro ◽

...

Keyword(s):

Bladder Cancer ◽

Smoking Cessation ◽

Risk Factor ◽

Cancer Patients ◽

Smoking Prevalence ◽

Smoking History ◽

High Current ◽

Cross Sectional ◽

Current Smoking ◽

Quitting Smoking

Introduction: Smoking is an important risk factor for the development, recurrence and progression of bladder cancer. Our aim was to analyze smoking habits after diagnosis in bladder cancer patients. Additionally, we evaluated patient knowledge about smoking as a risk factor and the urologist role in promoting abstinence.Material and Methods: A cross-sectional, observational and descriptive study was performed in bladder cancer patients, diagnosed between January 2013 and September 2015 (n = 160) in Braga Hospital, in Portugal.Results: Smoking history was present in 71.9% of the sample, with 21.9% current smokers, (40.7% of abstinence after diagnosis). Smoking was acknowledged as a risk factor by 74.4% of the sample, with only 51.3% of ever smokers and 24.4% of non-smokers recognizing smoking as the leading risk factor (p = 0.008). The presence of other household smokers were significantly higher in patients who continued smoking (40%) than in ex-smokers after diagnosis (4.2%) (p = 0.005). The majority of smokers at diagnosis (83.1%) were advised to quit by their urologist, but only one smoker (1.7%) was offered any specific intervention to aid in cessation.Discussion: Smoking is not recognized as the leading risk factor for bladder cancer. This limited awareness, associated with the known difficulties in quitting smoking and the observed lack of smoking cessation interventions, may account for the high current smoking prevalence, albeit in line with other studies.Conclusion: This study highlights the need for efficient smoking cessation programs directed to bladder cancer patients.

Download Full-text